Research & Regulatory News
What the Systematic Reviews Say About Children and Adolescents
Two systematic reviews with meta-analysis published in 2025 assessed GLP-1 receptor agonists in children and adolescents — Kotecha and colleagues in JAMA Pediatrics and Sedenho-Prado and colleagues in the International Journal of Obesity.
Key facts
- Kotecha 2025
- JAMA Pediatr, 1 December (PMID 40952752)
- Sedenho-Prado 2025
- Int J Obes, August (PMID 40269110)
- Design
- Systematic review and meta-analysis
- Populations
- Children and adolescents
- Landmark trial
- STEP TEENS, NEJM 2022
- Still absent
- Long-term follow-up data
Why review-level evidence appeared when it did
Systematic reviews require a body of primary studies to review. Two independent meta-analyses appearing in 2025 indicates enough paediatric trials had accumulated to make pooling worthwhile — which is itself a statement about how quickly this field moved after the adult approvals.
What a meta-analysis adds over individual trials
Precision and breadth. Pooling across studies narrows confidence intervals and can detect adverse events too infrequent to appear reliably in any single trial. It also assesses the quality of the underlying evidence, which individual papers do not do for themselves.
Research material referenced
Retatrutide 10mg — third-party HPLC tested
What it cannot add
Duration. A meta-analysis of 68-week trials produces a more precise estimate of what happens over 68 weeks; it cannot say anything about year five. Pooling more short studies never becomes a long study, and that is the specific limitation that matters most for a population who may be treated for decades.
The two reviews cover different ground
Kotecha and colleagues addressed efficacy and safety in children and adolescents with obesity or type 2 diabetes in JAMA Pediatrics. Sedenho-Prado and colleagues addressed metabolic outcomes and safety in children and adolescents with obesity in the International Journal of Obesity. Overlapping but distinct questions, published independently in the same year.
Where the underlying trials sit
STEP TEENS remains the landmark, with 201 randomised adolescents over 68 weeks. Tirzepatide's adolescent Phase 3, NCT06075667, reached primary completion in June 2026 with 160 participants aged 12 to 17. The evidence base is real and it is young.
The boundary this site maintains
Everything described concerns licensed medicines and registered trials in paediatric populations, conducted under clinical supervision with ethics approval and specialist oversight. Nothing supplied here is any of those compounds, is an alternative to them, or has any place in the care of a child.
Extended research context
The Research & Regulatory News deep dive
Deep dive: why 2026 was the year the incretin field split in two
For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.
Deep dive: what a marketing authorisation actually means
An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.
Deep dive: reading trial results without being misled
Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.
Research applications
- ▸Tracking regulatory status of investigational incretin compounds
- ▸Understanding the difference between authorisation, NICE appraisal and NHS availability
- ▸Comparing peptide and non-peptide receptor agonist pharmacology
- ▸Interpreting Phase 3 topline releases before peer-reviewed publication
- ▸Verifying trial identity against ClinicalTrials.gov registrations
Handling checklist
- ✓Check the compound named in a trial registration matches the compound being discussed
- ✓Confirm the NCT identifier resolves to the acronym being cited
- ✓Read topline press releases as preliminary until peer-reviewed publication
- ✓Separate the trial population from the headline percentage before comparing studies
- ✓Treat authorisation in one jurisdiction as saying nothing about status in another
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Treating a positive Phase 3 as approval
Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.
✗ Comparing weight-reduction percentages across different trials
Fix: Population, duration and comparator differ; the numbers are not interchangeable.
✗ Assuming one incretin's approval legitimises another compound
Fix: Authorisations are product-specific and do not transfer between compounds.
✗ Citing a TRIUMPH number without checking the NCT identifier
Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.
✗ Reading research material as an alternative to a licensed medicine
Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is orforglipron a peptide?
- Has retatrutide been approved by the MHRA?
- What did TRIUMPH-1 actually report?
- Why can orforglipron be taken as a tablet when peptides cannot?
- Are research peptides legal in the UK?
- What is the difference between MHRA authorisation and NHS availability?
Frequently asked questions
- Is there systematic review evidence in children?
- Yes — two independent systematic reviews with meta-analysis published in 2025, in JAMA Pediatrics and the International Journal of Obesity.
- Does pooling trials tell us about long-term effects?
- No. Pooling 68-week trials gives a more precise estimate of 68 weeks. It never becomes a long-term study.
- What is the landmark paediatric trial?
- STEP TEENS, published in NEJM in December 2022 — 201 randomised adolescents over 68 weeks.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedKotecha P et al., Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis — JAMA Pediatr 2025 (PMID 40952752)pubmed.ncbi.nlm.nih.gov
- PubMedSedenho-Prado LG et al., Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity — Int J Obes 2025 (PMID 40269110)pubmed.ncbi.nlm.nih.gov
- PubMedWeghuber D et al., Once-Weekly Semaglutide in Adolescents with Obesity — NEJM 2022 (PMID 36322838)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Tirzepatide in adolescents (NCT06075667)clinicaltrials.gov
- RefMHRA · Medicines and Healthcare products Regulatory Agencygov.uk
- RefNICE · National Institute for Health and Care Excellencenice.org.uk
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066) — Retatrutide pivotal obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · ATTAIN-1 (NCT05869903) — Orforglipron in obesity/overweightclinicaltrials.gov
- RefEli Lilly · TRIUMPH-1 topline results (May 2026)investor.lilly.com
- PubMedOrforglipron: A Comprehensive Review — Int J Mol Sci 2026 (PMID 41683830)pubmed.ncbi.nlm.nih.gov
- RefMHRA Yellow Card — report a defective or falsified medicineyellowcard.mhra.gov.uk
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More Research & Regulatory News articles
- What the Human Studies Have FoundA BMJ Scandinavian cohort, a JAMA Network Open analysis of 13 cancers, and a 2025 meta-analysis of randomised trials. What each design can support.
- Semaglutide in Obesity-Related Heart FailureKosiborod 2023 in NEJM and a pooled Lancet analysis in 2024. Randomised evidence in HFpEF, which is a stronger design than the observational work.
- STRIDE and the Qualifier That Keeps Getting DroppedA phase 3b randomised trial of semaglutide in symptomatic PAD — and type 2 diabetes. The diabetes criterion is in the title and rarely survives summary.
- A Trial That Had to Move Two Things at Once407 participants, Phase 3, with co-primary endpoints of body weight and WOMAC pain score. Published in NEJM in October 2024.
- A Nationwide Cohort, and a Result That Points Away From the DrugDanish registries, 2009 to 2023. Preterm birth risk was raised in the diabetes indication but not in weight management — which is the finding.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchHow One Peptide Engages Three Receptors
- GHK-Cu (Copper Peptide)GHK-Cu in the Published Literature
- TB-500 (Thymosin β4 fragment)BPC-157 and TB-500 Together: What the Evidence Says
- BPC-157 (Pentadecapeptide)BPC-157 Studied Effects, Sorted by Evidence
- CJC-1295 & IpamorelinStorage and Reconstitution for Both Compounds
- Peptide ReferenceEndotoxin: The Contaminant That Is Not a Protein
- Bacteriostatic WaterThe Diluent Makes Freeze-Thaw Worse
- GLP-1 & Incretin ScienceThe Method Determines the Number
- MOTS-c (Mitochondrial Peptide)MOTS-c Structure, Sequence and Physical Properties
- Semax (ACTH Fragment Peptide)Semax Structure, Sequence and Physical Properties
- Selank (Tuftsin Analogue)Selank's Enkephalinase Mechanism
- DSIP (Delta Sleep-Inducing Peptide)The Missing Biology: No Gene, No Precursor, No Receptor
- KLOW (Blend)KLOW Regulatory Status
- GLOW (Blend)GLOW Regulatory Status
- MT-2 (Melanotan II)Five Melanocortin Receptors, Not One
- IGF-1 LR3Recombinant Versus Synthetic: Two Different Quality Problems
- GlutathioneGSH and GSSG: What the Ratio Measures
- NAD+The Membrane Problem: Why NAD+ Doesn't Get In
- KPVKPV Regulatory Status